Cynapsus Therapeutics (CYNA) Offers Update Ahead of Cowen & Co. Conference

Cynapsus Therapeutics Inc. (NASDAQ: CYNA) announced that President and CEO, Anthony Giovinazzo, will present a company overview and update today at the Cowen & Co., 36th Annual Health Care Conference. The presentation will take place at the Boston Marriott Copley Place Hotel at 1:20 p.m. EST in the Vineyard conference room on the 4th Floor.

Following the live presentation, a video webcast of the presentation will be available online at http://wsw.com/webcast/cowen30/cyna and the presentation materials will be available on the Cynapsus web site, www.cynapsus.ca, in the Investor’s section. The webcast will be archived for 90 days following the event.

The presentation includes updates on the Company’s development program including:

Clinical and Regulatory Activities (see detailed descriptions below)

• CTH-300 Phase 3 Efficacy Study: all sites are actively recruiting approximately 126 patients in total for the trial. Top-line data expected in the second or third quarter of 2016
• CTH-301 Phase 3 Safety Study: all sites are actively recruiting approximately 100 additional patients that will be added to patients brought in from the CTH-300 study. Top-line data expected in the fourth quarter of 2016 or the first quarter of 2017
• European Medicines Agency (EMA): meeting expected to occur in the second quarter of 2016
• CTH-302 European Registration Study: trial expected to commence in the second half of 2016
• CTH-201 Phase 2 Thorough QT Study: if required, this study is planned to begin in the second half of 2016, subject to FDA review and agreement. If commenced, the trial is expected to be completed in the fourth quarter of 2016 or the first quarter of 2017
• New Drug Application (“NDA”) submission expected near the end of 2016 or in early 2017

“We continue to make progress both in our clinical development of APL-130277 and in preparing for a commercial presence,” stated Anthony Giovinazzo, President and CEO. “We look forward to reporting further progress in 2016, and remain focused on completing our Phase 3 studies and filing our new drug application with the U.S. FDA near the end of 2016 or in early 2017.”

You May Also Be Interested In

• McCormick board member to resign after CFO appointment at Best Buy
• Electra Therapeutics files for proposed IPO
• Veeva Systems (VEEV) PT Raised at TD Cowen; '2Q Raise Suggests Strong Continued Momentum'